LEO Pharma announces that it has finalized the acquisition of the strategic asset TMB-001 as well as certain other assets from Timber Pharmaceuticals following its chapter 11 bankruptcy filing. The TMB-001 project aims to develop a topical treatment for multiple moderate to severe subtypes of congenital ichthyosis – a skin disease with significant unmet need and no approved prescription therapies available. The TMB-001 project continues as planned and without changes within LEO Pharma. All employees of Timber Pharmaceuticals will transition to LEO Pharma’s offices in New Jersey, US.
Read the full article: LEO Pharma Finalizes Acquisition of Key Assets from Timber Pharmaceuticals //
Source: https://www.businesswire.com/news/home/20240123892208/en/LEO-Pharma-Finalizes-Acquisition-of-Key-Assets-From-Timber-Pharmaceuticals